Xbrane Biopharma AB (publ) (XBRANE.ST)
Xbrane Biopharma AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Solna, AB, SE. The stock last traded at $10.60, up 1.92% on the session, giving a market capitalisation of $129.1M. Its beta of 0.85 implies it has historically moved less than the broad market.
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
Xbrane Biopharma AB (publ) is most often compared with the following Healthcare names: